ArticleFrontiers in oncology2025
Microvascular invasion and early recurrence of hepatocellular carcinoma after CT-guided radiofrequency ablation: risk factor analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictors of True Early Recurrence in Patients Undergoing Radiofrequency Ablation for Hepatocellular Carcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a major global health challenge, and microvascular invasion (MVI) and early recurrence pose significant obstacles to effective treatment. Identifying the risk factors associated with these complications following computed tomography (CT)-guided radiofrequency ablation (RFA) is essential for optimizing patient management and improving treatment outcomes. Methods: A retrospective analysis was conducted from January 2020 to January 2022, involving 186 patients who underwent CT-guided RFA for primary HCC at a single institution. The study assessed tumor characteristics, liver function, and post-treatment outcomes to identify predictors of MVI and early recurrence. Logistic regression and machine learning were employed to determine statistically significant risk factors. Results: Multiple tumors, incomplete capsules, irregular tumor margins, and rapid portal venous washout were identified as significant predictors of MVI. Similarly, rapid portal venous phase washout, tumor internal necrosis, MVI, multiple tumors, and incomplete capsule integrity were strongly associated with early recurrence. The results of the logistic regression machine learning further enhance the reliability of the current findings. Conclusion: Patients with HCC exhibiting certain high-risk features are susceptible to MVI and early recurrence following CT-guided RFA. The identified risk factors suggest the need for enhanced monitoring and personalized therapeutic strategies to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.